Global Metabolic Disorders Therapeutics Market 2017-2023 by Disease Type & Product - Market to Grow with a CAGR of 5.7% - ResearchAndMarkets.com

DUBLIN--()--The "Metabolic Disorders Therapeutics Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2023" report has been added to ResearchAndMarkets.com's offering.

The report predicts the global metabolic disorders therapeutics market to grow with a CAGR of 5.7% over the forecast period of 2017-2023. The study on metabolic disorders therapeutics market covers the analysis of the leading geographies such as North America, Europe, Asia-Pacific and RoW for the period of 2015 to 2023.

The report on metabolic disorders therapeutics market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global metabolic disorders therapeutics market over the period of 2015 to 2023. Moreover, the report is collective presentation of primary and secondary research findings.

Porter's five forces model in the report provides insights into the competitive rivalry, supplier and buyer positions in the market and opportunities for the new entrants in the global metabolic disorders therapeutics market over the period of 2015 to 2023. Further, Growth Matrix given in the report brings an insight on the investment areas that existing or new market players can consider.

Key Topics Covered:

1. Preface

1.1. Report Description

1.2. Research Methods

1.3. Research Approaches

2. Executive Summary

3. Global Metabolic Disorders Therapeutics Market Overview

3.1. Introduction

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

3.3. Porter's Five Forces Analysis

3.4. Growth Matrix Analysis

3.5. Competitive Landscape in the Global Metabolic Disorders Therapeutics Market

4. Global Metabolic Disorders Therapeutics Market by Disease Type

4.1. Diabetes

4.2. Obesity

4.3. Hypercholesterolemia

4.4. Lysosomal Storage Disease

5. Global Metabolic Disorders Therapeutics Market by Product

5.1. Metachromatic Leukodystrophy

5.2. Globoid Leukodystrophy

5.3. Hepatic Encephalopathy

5.4. Others

6. Global Metabolic Disorders Therapeutics Market by Region 2017-2023

7. Company Covered

  • Astazeneca Plc
  • Novo Nordisk
  • Sanofi
  • Merck
  • Eli Lily
  • AbbVie
  • Actelion Pharmaceuticals
  • Amicus Therapeutics
  • Arena Pharmaceuticals
  • Biocon

For more information about this report visit https://www.researchandmarkets.com/research/p4mlkp/global_metabolic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs